Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.21
INRLF's Cash to Debt is ranked lower than
63% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. INRLF: 0.21 )
INRLF' s 10-Year Cash to Debt Range
Min: 0.21   Max: 110.38
Current: 0.21

0.21
110.38
Equity to Asset 0.10
INRLF's Equity to Asset is ranked lower than
77% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INRLF: 0.10 )
INRLF' s 10-Year Equity to Asset Range
Min: 0.1   Max: 0.83
Current: 0.1

0.1
0.83
F-Score: 3
Z-Score: -2.65
M-Score: -4.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -55.10
INRLF's Operating margin (%) is ranked lower than
72% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. INRLF: -55.10 )
INRLF' s 10-Year Operating margin (%) Range
Min: -2674.1   Max: 12.9
Current: -55.1

-2674.1
12.9
Net-margin (%) -71.00
INRLF's Net-margin (%) is ranked lower than
72% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. INRLF: -71.00 )
INRLF' s 10-Year Net-margin (%) Range
Min: -2563.4   Max: 16
Current: -71

-2563.4
16
ROE (%) -30.90
INRLF's ROE (%) is ranked lower than
70% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. INRLF: -30.90 )
INRLF' s 10-Year ROE (%) Range
Min: -210.8   Max: 4.9
Current: -30.9

-210.8
4.9
ROA (%) -13.90
INRLF's ROA (%) is ranked lower than
64% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. INRLF: -13.90 )
INRLF' s 10-Year ROA (%) Range
Min: -113.3   Max: 3.7
Current: -13.9

-113.3
3.7
ROC (Joel Greenblatt) (%) -29.90
INRLF's ROC (Joel Greenblatt) (%) is ranked lower than
66% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. INRLF: -29.90 )
INRLF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -352.8   Max: 8.4
Current: -29.9

-352.8
8.4
Revenue Growth (%) -15.10
INRLF's Revenue Growth (%) is ranked lower than
92% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. INRLF: -15.10 )
INRLF' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 115.7
Current: -15.1

0
115.7
EBITDA Growth (%) -18.00
INRLF's EBITDA Growth (%) is ranked lower than
96% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. INRLF: -18.00 )
INRLF' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 4.8
Current: -18

0
4.8
EPS Growth (%) 5.90
INRLF's EPS Growth (%) is ranked lower than
91% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. INRLF: 5.90 )
INRLF' s 10-Year EPS Growth (%) Range
Min: 0   Max: 5.9
Current: 5.9

0
5.9
» INRLF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with INRLF



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.20
INRLF's P/B is ranked higher than
53% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. INRLF: 1.20 )
INRLF' s 10-Year P/B Range
Min: 0.77   Max: 6.72
Current: 1.2

0.77
6.72
P/S 2.50
INRLF's P/S is ranked higher than
58% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. INRLF: 2.50 )
INRLF' s 10-Year P/S Range
Min: 2.04   Max: 23.75
Current: 2.5

2.04
23.75
EV-to-EBIT 66.70
INRLF's EV-to-EBIT is ranked higher than
74% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INRLF: 66.70 )
INRLF' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 66.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 767.00
INRLF's Price/Net Current Asset Value is ranked lower than
54% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. INRLF: 767.00 )
INRLF' s 10-Year Price/Net Current Asset Value Range
Min: 27.1   Max: 2184
Current: 767

27.1
2184
Price/Tangible Book 68.20
INRLF's Price/Tangible Book is ranked higher than
51% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. INRLF: 68.20 )
INRLF' s 10-Year Price/Tangible Book Range
Min: 3.1   Max: 9.4
Current: 68.2

3.1
9.4
Price/Median PS Value 9.00
INRLF's Price/Median PS Value is ranked higher than
53% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. INRLF: 9.00 )
INRLF' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 5.1
Current: 9

0.7
5.1

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:ICLL.Netherlands, IJE.Germany
» More Articles for OTCPK:INRLF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide